Skip to main content

Gastritis

6
Pipeline Programs
9
Companies
9
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
1
0
2
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

9 companies ranked by most advanced pipeline stage

Young BioPharma
Young BioPharmaMA - Lowell
1 program
1
ALBISPhase 41 trial
Active Trials
NCT02175186Completed47Est. Jan 2019
Chong Kun Dang Pharmaceutical
2 programs
1
1
CKD-495 75mgPhase 31 trial
CKD-495 75mgPhase 21 trial
Active Trials
NCT03437785Completed250Est. Oct 2018
NCT04255589Completed242Est. May 2021
Hanmi Pharmaceutical
1 program
1
HIP2101Phase 31 trial
Active Trials
NCT05024721Completed326Est. Mar 2022
Daewon Pharma
Daewon PharmaKorea - Hwaseong
1 program
1
DW1903Phase 11 trial
Active Trials
NCT05155072Completed31Est. Sep 2020
ViiV Healthcare
ViiV HealthcareNC - Durham
1 program
1
Reference mosapride citratePhase 1
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
Antibiotic selection based on the antibiotic susceptibility testingN/A1 trial
Active Trials
NCT02689583Unknown3,000
Autonomous Therapeutics
1 program
WLE and then LCIN/A1 trial
Active Trials
NCT02724280Completed253Est. Feb 2017
GSK
GSKLONDON, United Kingdom
1 program
Reference mosapride citratePHASE_11 trial
Active Trials
NCT02201316Completed18Est. Mar 2014
GC Biopharma
GC BiopharmaKorea - Yongin
1 program
GC6101A 37.5mgPHASE_21 trial
Active Trials
NCT02353039Unknown200Est. Jul 2015

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Young BioPharmaALBIS
Hanmi PharmaceuticalHIP2101
Chong Kun Dang PharmaceuticalCKD-495 75mg
Chong Kun Dang PharmaceuticalCKD-495 75mg
GC BiopharmaGC6101A 37.5mg
Daewon PharmaDW1903
GSKReference mosapride citrate
Autonomous TherapeuticsWLE and then LCI
UNION therapeuticsAntibiotic selection based on the antibiotic susceptibility testing

Clinical Trials (9)

Total enrollment: 4,367 patients across 9 trials

NCT02175186Young BioPharmaALBIS

Effect of ALBIS on Gastroduodenal Mucosal Injury in Patients Receiving Dual Antiplatelet Therapy After Percutaneous Coronary Intervention

Start: Jan 2015Est. completion: Jan 201947 patients
Phase 4Completed
NCT05024721Hanmi PharmaceuticalHIP2101

Study to Evaluate the Efficacy and Safety of HIP2101 in Patients With Acute or Chronic Gastritis

Start: Aug 2021Est. completion: Mar 2022326 patients
Phase 3Completed
NCT04255589Chong Kun Dang PharmaceuticalCKD-495 75mg

A Clinical Trial to Evaluate the Efficacy and Safety of CKD-495

Start: Jan 2020Est. completion: May 2021242 patients
Phase 3Completed
NCT03437785Chong Kun Dang PharmaceuticalCKD-495 75mg

Clinical Trial to Evaluate the Efficacy and Safety of CKD-495 Tablet

Start: Jan 2018Est. completion: Oct 2018250 patients
Phase 2Completed
NCT02353039GC BiopharmaGC6101A 37.5mg

Phase II Study to Evaluate the Efficacy and Safety of GC6101A in Subjects With Gastritis

Start: Sep 2014Est. completion: Jul 2015200 patients
Phase 2Unknown
NCT05155072Daewon PharmaDW1903

Clinical Trial to Evaluate the Safety and Pharmacokinetic/Pharmacodynamic Characteristics of DW1903

Start: May 2020Est. completion: Sep 202031 patients
Phase 1Completed
NCT02201316GSKReference mosapride citrate

A Pilot Study to Determine the Relative Bioavailability of Mosapride 5mg From Two Candidate Formulations of GR107719B Relative to One 5mg Tablet of Reference Mosapride Citrate (GASMOTIN™) in Healthy Adult Human Subjects Under Fasting Conditions

Start: Feb 2014Est. completion: Mar 201418 patients
Phase 1Completed
NCT02724280Autonomous TherapeuticsWLE and then LCI

Linked Color Imaging to Differentiate H. Pylori Associated Gastritis and Gastric Atrophy

Start: Sep 2016Est. completion: Feb 2017253 patients
N/ACompleted
NCT02689583UNION therapeuticsAntibiotic selection based on the antibiotic susceptibility testing

A Multi-center Study for Individual Treatment of Helicobacter Pylori Infection

Start: Mar 20163,000 patients
N/AUnknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
9 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.